<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The treatment of patients with <z:e sem="disease" ids="C0004763" disease_type="Disease or Syndrome" abbrv="CELLO">Barrett's oesophagus</z:e> is controversial </plain></SENT>
<SENT sid="1" pm="."><plain>Debate exists regarding the use and value of high dose acid suppression as the standard of practice </plain></SENT>
<SENT sid="2" pm="."><plain>Despite prolonged use of high dose <z:chebi fb="0" ids="49200">proton pump inhibitors</z:chebi> (40 mg <z:chebi fb="14" ids="7772">omeprazole</z:chebi>, 60 mg <z:chebi fb="0" ids="6375">lansoprazole</z:chebi>), most studies have shown no convincing evidence of significant regression of Barrett's length </plain></SENT>
<SENT sid="3" pm="."><plain>These studies, however, have used fixed doses of <z:chebi fb="0" ids="49200">proton pump inhibitors</z:chebi> and did not regularly document control of oesophageal acid exposure </plain></SENT>
<SENT sid="4" pm="."><plain>AIM: To determine whether regression of Barrett's epithelium can be achieved with documented maximal acid suppression </plain></SENT>
<SENT sid="5" pm="."><plain>METHODS: We have prospectively followed nine patients with <z:e sem="disease" ids="C0004763" disease_type="Disease or Syndrome" abbrv="CELLO">Barrett's oesophagus</z:e> (eight male; mean age 60 years) for more than 1 year </plain></SENT>
<SENT sid="6" pm="."><plain>They were <z:hpo ids='HP_0000001'>all</z:hpo> treated using medical therapy with pH monitoring documenting oesophageal acid exposure over 24 h &lt; 1.6% of the time, and with two or more esophagogastroduodenoscopies performed by the same endoscopist </plain></SENT>
<SENT sid="7" pm="."><plain>RESULTS: Acid control was individually tailored and achieved with <z:chebi fb="0" ids="49200">proton pump inhibitor</z:chebi> b.d </plain></SENT>
<SENT sid="8" pm="."><plain>(<z:chebi fb="14" ids="7772">omeprazole</z:chebi> 20 mg or <z:chebi fb="0" ids="6375">lansoprazole</z:chebi> 30 mg) and <z:chebi fb="10" ids="8776">ranitidine</z:chebi> at bedtime (HS) (Ran) if necessary </plain></SENT>
<SENT sid="9" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> nine patients (100%) showed some evidence of regression </plain></SENT>
<SENT sid="10" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> nine patients (100%) showed a decrease in Barrett's length (mean 2 cm, range 1-3 cm) </plain></SENT>
<SENT sid="11" pm="."><plain>Six out of nine (66.67%) patients showed evidence of squamous islands on the last oesophagogastroduodenoscopy </plain></SENT>
<SENT sid="12" pm="."><plain>The mean total distal oesophageal acid exposure was 0.38% (range: 0-1.5%) </plain></SENT>
<SENT sid="13" pm="."><plain>The mean follow-up of patients was 54 months (range: 13-118 months) </plain></SENT>
<SENT sid="14" pm="."><plain>CONCLUSIONS: Consistent and individually tailored maximal acid suppression documented by pH-metry is achievable and may result in <z:mp ids='MP_0001258'>decreased length</z:mp> and development of squamous islands in patients with Barrett's epithelium </plain></SENT>
<SENT sid="15" pm="."><plain>This approach should be further evaluated as potentially the preferred medical treatment for these patients </plain></SENT>
</text></document>